Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. 2026 RYTELO net product revenue is expected in the range of $220 to $240 million. The company faces significant concentration risk with a single commercial product, but benefits from first-mover advantage in telomerase inhibition for blood cancers.
Cyborg Score Rationale
In 2024, Geron's revenue reached $76.99 million, an increase of 32,386% from 2023. While revenue momentum is strong, Geron's heavy reliance on Rytelo as its primary revenue driver presents a significant risk to the company's long-term stability. The company has adequate cash to fund operations but faces profitability challenges.
Top Insights
7 analysts rate GERN as "Buy" with a 12-month target of $3.0, representing 53.85% upside from current levels.
The company is conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other myeloid hematologic malignancies.
Geron is navigating a complex landscape within the biotechnology segment focused on hematologic malignancies.
The company's current level of cash, equivalents, and marketable securities will suffice to fund projected operating requirements for the foreseeable future.
Named Competitors
Lenalidomide and other IMiDs — Standard-of-care immunomodulatory agents for MDS
Luspatercept — Erythroid maturation agent for MDS with anemia
Azacitidine — DNA methyltransferase inhibitor for MDS
Recent Developments
(February 2026) New CEO restructuring and 2026 growth guidance of $220-240M RYTELO revenue